Un compuesto de fórmula I: <EMI FILE="01028467_1" ID="1" IMF=JPEG >En el queR1 se selecciona del grupo formado por:<EMI FILE="01028467_2" ID="2" IMF=JPEG >R2 se selecciona del grupo formado por: H, alquilo C1-6, cicloalquil C3-6-alquilo C0-6, Ar-alquilo C0-6, Het-alquilo C0-6, R9C(O)-, R9C(S)-, R9SO2- R9OC(O)-, R9R11NC(O)-, R9R11NC(S)-, R9(R11)NSO2-<EMI FILE="01028467_3" ID="3" IMF=JPEG >R3 se selecciona del grupo formado por: H, alquilo C1-6, cicloalquil C3-6-alquilo C0-6, alquenilo C2-6, alquinilo C2-6, Het-alquilo C0-6, Ar-alquilo C0-6, Ar-Ar-alquilo C0-6, Ar-Het-alquilo C0-6, Het-Ar-alquilo C0-6 y Het-Het-alquilo C0-6;R3 y R´ pueden estar conectados para formar un anillo de pirrolidina, piperidina o morfolina;R4 se selecciona del grupo formado por H; alquilo C1-6, cicloalquil C3-6-alquilo C0-6, Ar-alquilo C0-6, Het-alquilo C0-6; R5C(O)-, R5C(S)-, R5SO2-, R5OC(O)-, R5R12NC(O)-, y R5R12NC(S)-;R5 se selecciona del grupo formado por H, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquil C3-6-alquilo C0-6, alcanoilo C2-6, Ar-alquilo C0-6, y Het-alquilo C0-6; R6 se selecciona del grupo formado por: H, alquilo C1-6, Ar-alquilo C0-6, y Het-alquilo C0-6; R7 se selecciona del grupo formado por: H, alquilo C1-6, cicloalquil C3-6-alquilo C0-6, Ar-alquilo C0-6, Het-alquilo C0-6, R10C(O)-, R10C(S)-, R10SO2-, R10OC(O)-, R10R13NC(O)-, y R10R13NC(S)-;R8 se selecciona del grupo formado por: H, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, Het-alquilo C0-6, y Ar-alquilo C0-6;R9 se selecciona del grupo formado por: alquilo C1-6, cicloalquil C3-6-alquilo C0-6, Ar-alquilo C0-6, y Het-alquilo C0-6; - 2 -R10 se selecciona del grupo formado por: alquilo C1-6, cicloalquil C3-6-alquilo C0-6, Ar-alquilo C0-6 y Het-alquilo C0-6;R11 se selecciona del grupo formado por: H, alquilo C1-6, cicloalquil C3-6-alquilo C0-6 Ar-alquilo C0-6, y Het-alquilo C0-6; R12 se selecciona del grupo formado por: H, alquilo C1-6, Ar-alquilo C0-6, Het-alquilo C0-6;R13 se selecciona del grupo formado por: H, alquilo C1-6, Ar-alquilo C0-6, Het-alquilo C0-6;R´ se selecciona del grupo formado por: H, alquilo C1-6, Ar-alquilo C0-6, Het-alquilo C0-6;R´´ se selecciona del grupo formado por: H, alquilo C1-6, Ar-alquilo C0-6, o Het-alquilo C0-6;R´´´ es alquilo C1-6;X se selecciona del grupo formado por: CH2, S y O;Z se selecciona del grupo formado por: C(O) y CH2;n es un número entero de 1 a 5; y sus sales farmacéuticamente aceptables, hidratos y solvatos.A compound of formula I: <EMI FILE = "01028467_1" ID = "1" MFI = JPEG> In which R1 is selected from the group consisting of: <EMI FILE = "01028467_2" ID = "2" MFI = JPEG> R2 is selected from the group consisting of: H, C1-6 alkyl, C3-6 cycloalkyl-C0-6 alkyl, Ar-C0-6 alkyl, Het-C0-6 alkyl, R9C (O) -, R9C (S) -, R9SO2 - R9OC (O) -, R9R11NC (O) -, R9R11NC (S) -, R9 (R11) NSO2- <EMI FILE = "01028467_3" ID = "3" MFI = JPEG> R3 is selected from the group consisting of: H , C1-6 alkyl, C3-6 cycloalkyl-C0-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Het-C0-6 alkyl, Ar-C0-6 alkyl, Ar-Ar-C0-6 alkyl, Ar -Het-C0-6 alkyl, Het-Ar-C0-6 alkyl and Het-Het-C0-6 alkyl; R3 and R´ may be connected to form a pyrrolidine, piperidine or morpholine ring; R4 is selected from the group formed by H; C1-6 alkyl, C3-6 cycloalkyl-C0-6 alkyl, Ar-C0-6 alkyl, Het-C0-6 alkyl; R5C (O) -, R5C (S) -, R5SO2-, R5OC (O) -, R5R12NC (O) -, and R5R12NC (S) -; R5 is selected from the group consisting of H, C1-6 alkyl, C2 alkenyl -6, C2-6 alkynyl, C3-6 cycloalkyl-C0-6 alkyl, C2-6 alkanoyl, Ar-C0-6 alkyl, and Het-C0-6 alkyl; R6 is selected from the group consisting of: H, C1-6 alkyl, Ar-C0-6 alkyl, and Het-C0-6 alkyl; R7 is selected from the group consisting of: H, C1-6 alkyl, C3-6 cycloalkyl-C0-6 alkyl, Ar-C0-6 alkyl, Het-C0-6 alkyl, R10C (O) -, R10C (S) - , R10SO2-, R10OC (O) -, R10R13NC (O) -, and R10R13NC (S) -; R8 is selected from the group consisting of: H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Het- C0-6 alkyl, and Ar-C0-6 alkyl; R9 is selected from the group consisting of: C1-6 alkyl, C3-6 cycloalkyl-C0-6 alkyl, Ar-C0-6 alkyl, and Het-C0-6 alkyl ; - 2 -R10 is selected from the group consisting of: C1-6 alkyl, C3-6 cycloalkyl-C0-6 alkyl, Ar-C0-6 alkyl and Het-C0-6 alkyl; R11 is selected from the group consisting of: H, C1-6 alkyl, C3-6 cycloalkyl-C0-6 alkyl Ar-C0-6 alkyl, and Het-C0-6 alkyl; R12 is selected from the group consisting of: H, C1-6 alkyl, Ar-C0-6 alkyl, Het-C0-6 alkyl; R13 is selected from the group consisting of: H, C1-6 alkyl, Ar-C0-6 alkyl , Het-C0-6 alkyl; R 'is selected from the group consisting of: H, C1-6 alkyl, Ar-C0-6 alkyl, Het-C0-6 alkyl; R´´ is selected from the group consisting of: H, C1-6 alkyl, Ar-C0-6 alkyl, or Het-C0-6 alkyl; R´´´ is C1-6 alkyl; X is selected from the group consisting of: CH2, S and O; Z is selected from the group formed by: C (O) and CH2; n is an integer from 1 to 5; and its pharmaceutically acceptable salts, hydrates and solvates.